Agios Pharmaceuticals is a biopharmaceutical company focused on areas of hematologic malignancies, solid tumors and rare genetic diseases. Co.'s product, TIBSOVO® (ivosidenib) is for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase (IDH) 1 mutation. Co.'s other product is IDHIFA® (enasidenib) for patients with R/R AML and an IDH2 mutation. Co.'s pre-commercial clinical cancer product candidates include: vorasidenib, a brain-penetrant pan-IDH mutant inhibitor; and AG-270, an orally available selective inhibitor of methionine adenosyltransferase 2a. The AGIO stock yearly return is shown above.
The yearly return on the AGIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AGIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|